טוען...
DNA damage repair in ovarian cancer: unlocking the heterogeneity
Treatment for advanced ovarian cancer is rarely curative; three quarters of patients with advanced disease relapse and ultimately die with resistant disease. Improving patient outcomes will require the introduction of new treatments and better patient selection. Abrogations in the DNA damage respons...
שמור ב:
| הוצא לאור ב: | J Ovarian Res |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6011341/ https://ncbi.nlm.nih.gov/pubmed/29925418 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-018-0424-x |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|